Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Literature DB >> 12654677

Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Kim L Credito¹, Michael R Jacobs, Peter C Appelbaum.

Abstract

The activities of garenoxacin, ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, amoxicillin-clavulanate, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 20 anaerobes were tested. At two times the MIC, garenoxacin was bactericidal against 19 of 20 strains after 48 h and against 17 of 20 after 24 h. Other drugs, except clindamycin (which gave lower killing rates), gave killing rates similar to those for garenoxacin.

Entities: Chemical

Mesh：

Substances：

Year: 2003 PMID： 12654677 PMCID： PMC152516 DOI： 10.1128/AAC.47.4.1399-1402.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Authors: Matteo Bassetti; Louise M Dembry; Patricia A Farrel; Deborah A Callan; Vincent T Andriole
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

2. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: J Antimicrob Chemother Date: 1997-06 Impact factor: 5.790

3. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors: P C Appelbaum; S K Spangler; M R Jacobs
Journal: Antimicrob Agents Chemother Date: 1990-08 Impact factor: 5.191

4. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.

Authors: M R Jacobs; S K Spangler; P C Appelbaum
Journal: J Antimicrob Chemother Date: 1990-09 Impact factor: 5.790

5. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors: L M Ednie; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1998-09 Impact factor: 5.191

6. In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen Fernandez
Journal: Antimicrob Agents Chemother Date: 2002-03 Impact factor: 5.191

7. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1997-04 Impact factor: 5.191

8. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors: P C Appelbaum; S K Spangler; M R Jacobs
Journal: Antimicrob Agents Chemother Date: 1991-06 Impact factor: 5.191

9. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.

Authors: P C Appelbaum; S K Spangler; M R Jacobs
Journal: J Antimicrob Chemother Date: 1993-08 Impact factor: 5.790

Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

1. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

2. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.

3. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

4. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.

5. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

6. In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.

7. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

8. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

9. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.

Review 10. Quinolone activity against anaerobes: microbiological aspects.

1. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

Review 2. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

3. Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

4. Moxifloxacin in the treatment of skin and skin structure infections.